RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein
Bosco A. Paes, Paolo Manzoni, John R. Fullarton, Barry S. Rodgers-Gray, Xavier Carbonell-Estrany · 2026
Read RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein by Bosco A. Paes, Paolo Manzoni, John R. Fullarton, Barry S. Rodgers-Gray, Xavier Carbonell-Estrany (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13417266.txt.
Description
Bosco A Paes and colleagues review prevention of respiratory syncytial virus in infants in a 2026 article. The virus causes about 33 million lower airway infections yearly in children under five. For 28 years one antibody, given monthly, guarded only high risk babies. New long acting antibodies and a maternal vaccine have changed the field.
Two new antibodies, nirsevimab and clesrovimab, protect for a season after one dose and can cover all infants. Trials suggest protection against severe disease is broadly similar across products, with good safety. Real world proof is strong for nirsevimab and still lacking for the newest option. Cost and local supply should guide choices.
Catalog record
| CREATOR | Bosco A. Paes, Paolo Manzoni, John R. Fullarton, Barry S. Rodgers-Gray, Xavier Carbonell-Estrany |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49957 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |